Stroke and recurrent left atrial appendage thrombus in a patient with atrial fibrillation under old and new oral anticoagulants: A case report

Miklos Rohla; Matthias K. Freynhofer; Herbert Hammerl; Thomas W. Weiss; Kurt Huber

doi:10.1160/TH13-06-0446

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 111(02): 375-378
DOI: 10.1160/TH13-06-0446

Letters to the Editor

Schattauer GmbH

Stroke and recurrent left atrial appendage thrombus in a patient with atrial fibrillation under old and new oral anticoagulants: A case report

Authors

Miklos Rohla

¹3^rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
Matthias K. Freynhofer

¹3^rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
Herbert Hammerl

¹3^rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
Thomas W. Weiss

¹3^rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
Kurt Huber

¹3^rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria

Abstract

Full Text

References

References
1 Go AS, Hylek EM, Phillips KA. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.. J Am Med Assoc 2001; 285: 2370-2375.
2 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.. Stroke 1991; 22: 983-988.
3 van Walraven C, Hart RG, Singer DE. et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.. J Am Med Assoc 2002; 288: 2441-2448.
4 Huisman MV, Lip GY, Diener HC. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.. Thromb Haemost 2012; 107: 838-847.
5 Turpie AG, Kreutz R, Llau J. et al. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.. Thromb Haemost 2012; 108: 876-886.
6 Shen X, Li H, Rovang K. et al. Prevalence of intraatrial thrombi in atrial fibrillation patients with subtherapeutic international normalized ratios while taking conventional anticoagulation.. Am J Cardiol 2002; 90: 660-662.
7 Stoddard MF, Dawkins PR, Prince CR. et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardio-graphic study.. J Am Coll Cardiol 1995; 25: 452-459.
8 Dec GW, Fuster V. Idiopathic dilated cardiomyopathy.. N Engl J Med 1994; 331: 1564-1575.
9 Homma S, Thompson JL, Pullicino PM. et al. Warfarin and aspirin in patients with heart failure and sinus rhythm.. N Engl J Med 2012; 366: 1859-1869.
10 Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system.. Ann Int Med 2003; 138: 128-134.
11 O’Donnell J, Tuddenham EG, Manning R. et al. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction.. Thromb Haemost 1997; 77: 825-828.
12 Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis.. Arterioscler Thromb Vasc Biol 2001; 21: 731-738.
13 Kyrle PA, Minar E, Hirschl M. et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.. N Engl J Med 2000; 343: 457-462.
14 Folsom AR, Rosamond WD, Shahar E. et al. Prospective study of markers of hemostatic function with risk of ischaemic stroke.. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999; 100: 736-742.
15 Edwards FH, Hale D, Cohen A. et al. Primary cardiac valve tumors.. Ann Thorac Surg 1991; 52: 1127-1131.
16 Chahinian AP GD, Fuster V. Tumors of the Heart and Great Vessels.. In: Holland-Frei Cancer Medicine; 5th ed.; 2000
17 Butterworth JS, Poindexter CA. Papilloma of cusp of the aortic valve.. Report of a patient with sudden death. Circulation 1973; 48: 213-215.
18 Zurru MC, Romano M, Patrucco L. et al. Embolic stroke secondary to cardiac papillary fibroelastoma.. Neurologist 2008; 14: 128-130.
19 Mutlu H, Demir IE, Leppo J. et al. Nonsurgical management of a left ventricular pedunculated papillary fibroelastoma: a case report.. J Am Soc Echocardiogr 2008; 21: 877e4-7.
20 Holmes DR, Reddy VY, Turi ZG. et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.. Lancet 2009; 374: 534-542.
21 Nagarakanti R, Ezekowitz MD, Oldgren J. et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.. Circulation 2011; 123: 131-136.
22 Hylek EM, Go AS, Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.. N Engl J Med 2003; 349: 1019-1026.
23 Fang MC, Chang Y, Hylek EM. et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation.. Ann Int Med 2004; 141: 745-752.
24 Mueck W, Borris LC, Dahl OE. et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.. Thromb Hae-most 2008; 100: 453-461.